Evy Reviers is the daughter of a patient living with Amyotrophic Lateral Sclerosis (ALS).
As Chief Executive Officer of ALS Liga Belgium since 2006, Evy Reviers performs the general management of the organisation and coordinates the support to Belgian ALS patients. She has obtained several priority procedures to increase the quality of life of ALS patients in Belgium. At the European level, she is the Chairwoman of EUpALS, the European Organisation for Professionals and Patients with ALS, and defends the rights of ALS patients in scientific advice procedures at EMA. She is also a member of the ALS Dream Team, the Rare Diseases Organisation Belgium, the Drug Information Association, and EURORDIS. Between 2010 and 2016, she was a member of the Board of Directors of the International Alliance of ALS/MND Associations. She is member of the Executive Board of TRICALS.
Connect
Connect trials
RT001 in Amyotrophic Lateral Sclerosis
In this phase 2 trial, we will study the safety and efficacy of the compound RT001 in people living with ALS. This clinical trial is sponsored by Retrotope Inc.
ALXN1210-ALS-308 trial
This phase 3 trial aims to study the safety and efficacy of the drug ‘ravulizumab’ in people living with ALS. To register for this study, you should contact your local ALS centre or treating physician.
VALOR study
Biogen is conducting a clinical trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS) with a SOD1 gene mutation.
TUDCA-ALS
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.